Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
18.04. | AKTIE IM FOKUS: Sartorius und Tochter Stedim nach schwachen Zahlen unter Druck | 375 | dpa-AFX | FRANKFURT (dpa-AFX) - Schwächer als erwartet ausgefallene Quartalszahlen haben die Vorzugsaktien von Sartorius am Donnerstag stark belastet. Die Papiere des Pharma- und Laborzulieferers sackten zwischenzeitlich... ► Artikel lesen | |
18.04. | Sartorius Stedim Biotech SA: Sartorius Stedim Biotech publishes unaudited first quarter results for 2024 | 414 | EQS Group (EN) | Sartorius Stedim Biotech SA
/ Key word(s): Quarter Results
Sartorius Stedim Biotech publishes unaudited first quarter results for 2024 18-Apr-2024 / 07:02 CET/CEST
Aubagne... ► Artikel lesen | |
02.04. | Dividendenbekanntmachungen (02.04.2024) | 5.684 | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) BANCO BRADESCO SA BRBBDCACNPR8 0,0189 BRL 0,0035 EUR BANCO BRADESCO SA ADR US0594604029 0,0034 USD 0,0032 EUR BANCO BRADESCO SA... ► Artikel lesen | |
02.04. | Sartorius Stedim Biotech SA: Declaration Relative to the Number of Shares and Voting Rights Making up the Issued Capital | 278 | Dow Jones News | DJ Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: DECLARATION... ► Artikel lesen | |
01.04. | Sartorius Stedim Biotech S.A. goes ex dividend tomorrow | 4 | Seeking Alpha | ||
26.03. | Sartorius Stedim Biotech SA: Resolutions of the Annual Shareholders' Meeting of Sartorius Stedim Biotech S.A. | 304 | EQS Group (EN) | Sartorius Stedim Biotech SA
/ Key word(s): AGM/EGM
Resolutions of the Annual Shareholders' Meeting of Sartorius Stedim Biotech S.A. 26-March-2024 / 16:18 CET/CEST
Aubagne, France... ► Artikel lesen | |
01.03. | Sartorius Stedim Biotech SA: Declaration Relative to the Number of Shares and Voting Rights Making up the Issued Capital | 342 | Dow Jones News | DJ Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: DECLARATION... ► Artikel lesen | |
16.02. | Sartorius Stedim Biotech SA: Sartorius Stedim Biotech releases Universal Registration Document 2023 | 466 | EQS Group (EN) | Sartorius Stedim Biotech SA
/ Key word(s): Annual Results
Sartorius Stedim Biotech releases Universal Registration Document 2023 16-Feb-2024 / 10:00 CET/CEST
Aubagne, February... ► Artikel lesen | |
16.02. | Sartorius Stedim Biotech: Information on Document Availability | 349 | Dow Jones News | DJ Sartorius Stedim Biotech: Information on Document Availability
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech: Information on Document Availability
16-Feb-2024 / 09:23 CET/CEST
Dissemination... ► Artikel lesen | |
07.02. | Sartorius Stedim Biotech SA: Board of Directors of Sartorius Stedim Biotech resolves to propose a dividend of 0.69 euros per share to the Annual Shareholders' Meeting | 522 | Dow Jones News | DJ Board of Directors of Sartorius Stedim Biotech resolves to propose a dividend of 0.69 euros per share to the Annual Shareholders' Meeting
Sartorius Stedim Biotech SA / Key word(s): Dividend/AGM/EGM... ► Artikel lesen | |
07.02. | ROUNDUP/Schuldenabbau: Sartorius verkauft Aktien - Stedim mit Kapitalerhöhung | 429 | dpa-AFX | GÖTTINGEN/PARIS (dpa-AFX) - Der Pharma- und Laborausrüster Sartorius hat am Markt eigene Vorzugsaktien im Volumen von 200 Millionen Euro verkauft. Nach der teuren Übernahme des Zell- und Gentherapiespezialisten... ► Artikel lesen | |
07.02. | Sartorius Stedim Biotech SA: Sartorius Stedim Biotech S.A. successfully completes a EUR 1.2 billion share capital increase without shareholders' preferential subscription rights | 441 | EQS Group (EN) | Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: Sartorius Stedim Biotech S.A. successfully completes a EUR 1.2 billion share capital increase without shareholders' preferential subscription... ► Artikel lesen | |
06.02. | Sartorius-Tochter Stedim Biotech will Kapital um 1,2 Mrd Euro erhöhen | 592 | Dow Jones News | DJ Sartorius-Tochter Stedim Biotech will Kapital um 1,2 Mrd Euro erhöhen
FRANKFURT (Dow Jones)--Die französische Tochter des Laborausrüsters Sartorius, Sartorius Stedim Biotech (SBB), will ihr... ► Artikel lesen | |
06.02. | Sartorius Stedim Biotech SA: Sartorius Stedim Biotech S.A. announces an offering of approximately 1.2 billion euros of new shares without shareholders' preferential subscription rights by means of an accelerated bookbuilding | 374 | EQS Group (EN) | Sartorius Stedim Biotech SA
Sartorius Stedim Biotech S.A. announces an offering of approximately 1.2 billion euros of new shares without shareholders' preferential subscription rights by means... ► Artikel lesen | |
01.02. | Sartorius Stedim Biotech SA: Declaration Relative to the Number of Shares and Voting Rights Making up the Issued Capital | 379 | Dow Jones News | DJ Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: DECLARATION... ► Artikel lesen | |
26.01. | Sartorius Stedim Biotech S.A. GAAP EPS of €3.36, revenue of €2.77B | 7 | Seeking Alpha | ||
26.01. | Sartorius Stedim Biotech SA: Sartorius Stedim Biotech publishes preliminary, unaudited results for fiscal 2023 and provides 2024 guidance as well as new midterm outlook | 762 | EQS Group (EN) | Sartorius Stedim Biotech SA
/ Key word(s): Annual Results/Preliminary Results
Sartorius Stedim Biotech publishes preliminary, unaudited results for fiscal 2023 and provides 2024... ► Artikel lesen | |
25.01. | Top of the Street: Puma, UniCredit, Sartorius Stedim Biotech | 33 | Reuters | ||
05.01. | Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech | 494 | Dow Jones News | DJ Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: Half-year liquidity contract statement... ► Artikel lesen | |
03.01. | Sartorius Stedim Biotech SA: Declaration Relative to the Number of Shares and Voting Rights Making up the Issued Capital | 357 | Dow Jones News | DJ Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: DECLARATION... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
EVOTEC | 9,235 | +0,82 % | Bayer, Medigene, Evotec - Pharma und Biotech aus Deutschland sind wieder en vogue | Im Oktober letzten Jahres war das einstige deutsche Biotech-Vorzeigeunternehmen MorphoSys am Boden. Die Aktie war von 146,30 EUR bis auf 14,52 EUR abgesackt. Das galt auch für den gesamten Biotech-Sektor... ► Artikel lesen | |
QIAGEN | 38,760 | +2,16 % | QIAGEN N.V.: QIAGEN erweitert Tuberkulose-Portfolio: Neues NGS-Panel unterstützt Echtzeit-Überwachung und Bekämpfung antimikrobieller Resistenzen | QIAseq xHYB Mycobacterium tuberculosis Panel zu Forschungszwecken ermöglicht kulturfreies Whole Genome Sequencing komplexer Proben // Panel beschleunigt Nachverfolgung von TB-Ausbrüchen und unterstützt... ► Artikel lesen | |
CULLINAN THERAPEUTICS | 25,300 | +31,43 % | PEGY, CGEM and IFBD among mid-day movers | ||
RECURSION PHARMACEUTICALS | 8,120 | +3,57 % | Recursion Pharmaceuticals' Options Frenzy: What You Need to Know | ||
CABALETTA BIO | 11,010 | -9,61 % | Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | - First patient dosed with CABA-201 in the RESET (REstoring SElf-Tolerance) clinical trial program - - Initial clinical data from each of the first patients in the RESET-Myositis and RESET-SLE trials... ► Artikel lesen | |
SPRINGWORKS THERAPEUTICS | 45,530 | +3,01 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting | ||
IMMUNOVANT | 27,170 | -2,09 % | Should You Hold Immunovant (IMVT)? | ||
KEROS THERAPEUTICS | 57,86 | +6,77 % | Prozessmanagement in der Gemeinschaftsverpflegung / Keros Consult optimiert Warenwirtschaft für Eichhof-Stiftung Lauterbach | Düsseldorf (ots) - Ab sofort unterstützt Keros Consult, eine hundertprozentige Tochtergesellschaft der Klüh-Gruppe, die Eichhof-Stiftung Lauterbach bei der Optimierung ihrer Bestell- und Produktionsprozesse... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 24,360 | +2,22 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, April 22, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide... ► Artikel lesen | |
DYNE THERAPEUTICS | 24,730 | +4,37 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer | WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for... ► Artikel lesen | |
ARCELLX | 51,92 | +1,05 % | Should You Be Bullish on Arcellx (ACLX)? | ||
DAY ONE BIOPHARMACEUTICALS | 14,920 | +12,94 % | Day One Biopharmaceuticals, Inc.: Day One's OJEMDA (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor | First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation RAPNO LGG overall response rate... ► Artikel lesen | |
BIONTECH | 82,40 | +2,11 % | BioNTech SE: BioNTech veröffentlicht am 6. Mai 2024 Ergebnisse für das erste Quartal 2024 und informiert über operativen Fortschritt | MAINZ, Deutschland, 22. April 2024(Nasdaq: BNTX, "BioNTech" oder "das Unternehmen") wird am Montag, den 6. Mai 2024, die Ergebnisse für das erste Quartal 2024 veröffentlichen. Darüber hinaus wird das... ► Artikel lesen | |
KYMERA THERAPEUTICS | 33,370 | +0,06 % | Kymera Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) | ||
NUVALENT | 66,86 | +1,20 % | Nuvalent, Inc.: Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024 | Preclinical data continue to support NVL-330's broad activity against HER2 oncogenic alterations, selectivity over wild-type EGFR, and differentiated brain-penetrant profile
Zidesamtinib shown to... ► Artikel lesen |